NVLNF has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NVLNF has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Novelion Therapeutics's share price for the quarter that ended in Mar. 2019 was $1.23. Novelion Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Mar. 2019 was 19.0 Mil. Therefore, Novelion Therapeutics's market cap for the quarter that ended in Mar. 2019 was $23.4 Mil.
Novelion Therapeutics's quarterly market cap declined from Sep. 2018 ($55.8 Mil) to Dec. 2018 ($16.0 Mil) but then increased from Dec. 2018 ($16.0 Mil) to Mar. 2019 ($23.4 Mil).
Novelion Therapeutics's annual market cap declined from Dec. 2016 ($156.0 Mil) to Dec. 2017 ($58.4 Mil) and declined from Dec. 2017 ($58.4 Mil) to Dec. 2018 ($16.0 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Novelion Therapeutics's Enterprise Value for Today is $13.8 Mil.
The historical data trend for Novelion Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novelion Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec09 | Dec10 | Dec11 | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | |||||||||||
Market Cap | Get a 7-Day Free Trial | 151.96 | 104.07 | 156.03 | 58.35 | 15.97 |
Novelion Therapeutics Quarterly Data | ||||||||||||||||||||
Jun14 | Sep14 | Dec14 | Mar15 | Jun15 | Sep15 | Dec15 | Mar16 | Jun16 | Sep16 | Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | |
Market Cap | Get a 7-Day Free Trial | 65.46 | 69.38 | 55.81 | 15.97 | 23.42 |
For the Biotechnology subindustry, Novelion Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Novelion Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Novelion Therapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Novelion Therapeutics's Market Cap for the fiscal year that ended in Dec. 2018 is calculated as
Market Cap (A: Dec. 2018 ) | = | Share Price (A: Dec. 2018 ) | * | Shares Outstanding (EOP) (A: Dec. 2018 ) |
= | $0.84 | * | 19.017 | |
= | $16.0 |
Novelion Therapeutics's Market Cap for the quarter that ended in Mar. 2019 is calculated as
Market Cap (Q: Mar. 2019 ) | = | Share Price (Q: Mar. 2019 ) | * | Shares Outstanding (EOP) (Q: Mar. 2019 ) |
= | $1.23 | * | 19.043 | |
= | $23.4 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novelion Therapeutics (OTCPK:NVLNF) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Thank you for viewing the detailed overview of Novelion Therapeutics's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Kevin Kotler | 10 percent owner | C/O BROADFIN CAPITAL, LLC, 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022 |
Broadfin Capital, Llc | 10 percent owner | 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022 |
Broadfin Healthcare Master Fund Ltd | 10 percent owner | C/O 20 GENESIS CLOSE, ANSBACHER HOUSE, 2ND FLOOR, PO BOX 1344, GRAND CAYMAN E9 KY1-1108 |
Stonepine Capital, L.p. | 10 percent owner | 919 NW BOND STREET, SUITE 204, BEND OR 97703 |
Michael Dennis Price | officer: Chief Financial Officer | |
Benjamin Harshbarger | officer: See Remarks | ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142 |
Mark Dipaolo | director | 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830 |
John J Orloff | director | C/O BAXALTA INCORPORATED 1200 LAKESIDE DRIVE BANNOCKBURN IL 60015 |
Stephen L Sabba | director | DORSET MANAGEMENT CORP, 485 UNDERHILL BLVD SUITE 205, SYOSSET NY 11791 |
Mark Corrigan | director | |
Suzanne Louise Bruhn | director | C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, SUITE 250, AUSTIN TX 78746 |
John C Thomas | director | 8601 SIX FORKS ROAD, SUITE 160, RALEIGH NC 27615 |
Murray Stewart | officer: Executive Vice President, R&D | C/O NOVELION THERAPEUTICS INC., 1800-510 WEST GEORGIA STREET, VANCOUVER A1 V6B OM3 |
Jason Aryeh | director | 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037 |
Mary T Szela | director, officer: Chief Executive Officer | 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121 |
From GuruFocus
By Marketwired Marketwired • 06-24-2019
By Marketwired Marketwired • 05-21-2019
By Marketwired Marketwired • 09-24-2018
By Marketwired Marketwired • 11-21-2018
By Marketwired Marketwired • 10-08-2019
By GlobeNewswire GlobeNewswire • 03-31-2019
By GlobeNewswire GlobeNewswire • 08-21-2019
By Marketwired Marketwired • 07-31-2018
By Marketwired Marketwired • 07-17-2019
By Marketwired Marketwired • 03-31-2019
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.